Drugs / RTx-021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07439887 | Jan 2026 → Dec 2030 expected | Stargardt disease | Ray Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTx-021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07439887 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “investigational optogenetic gene therapy” NCT07439887 ↗ |
| Route | Intravitreal | “intravitreal injection” NCT07439887 ↗ |